• Mehfooj Ali
• Mohd Qamar
• Ms Kriti Dabral

Given that molecular evidence for tuberculosis (TB) dates back over 17,000 years, it is one of humanity's oldest diseases. The fact that TB is among the top 10 infectious diseases that kill people worldwide, second only to HIV, despite advances in detection and treatment methods, is regrettable. The World Health Organization (WHO) asserts that TB is a global pandemic. It is one of the main reasons why persons with HIV pass away. If a patient contracts Multi-Drug Resistant Tuberculosis (MDRT), the process is extended to 24 to 28 months of Directly Observed Treatment with short course chemotherapy (DOTS) and other medications. It requires the right dose at least 6 to 8 months to cure TB. Women's department of ONGC, school education, and integrated child development services (ICDS) are used to spread and sanitise society. Different treatment modalities are provided through the programme depending on the anti-microbial nature of the condition. Isoniazid-H, Rifampicin-R, Pyrazinamide-Z, and Ethambutol-E are the four first-line medications that are provided as a six-month, short course to new cases and those who don't show any signs of resistance.

MYCOBACTERIUM TUBERCULOSIS, RIFAMPICIN, PYRAZINAMIDE, ETHAMBUTOL, ISONIAZID

"Marketing survey of tuberculosis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 11, page no.d149-d153, November-2022, Available :http://www.jetir.org/papers/JETIR2211322.pdf

"Marketing survey of tuberculosis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 11, page no. ppd149-d153, November-2022, Available at : http://www.jetir.org/papers/JETIR2211322.pdf